//www.koonmotors.com/news/health_medicine/lymphoma/ Learn about lymphoma. Read the latest research on lymphoma symptoms, diagnosis, current lymphoma treatments. Find information on different lymphoma types including non-Hodgkin's lymphoma. en-us Wed, 05 Jul 2023 16:16:44 EDT Wed, 05 Jul 2023 16:16:44 EDT 60 //www.koonmotors.com/images/scidaily-logo-rss.png//www.koonmotors.com/news/health_medicine/lymphoma/ For more science news, visit ScienceDaily. //www.koonmotors.com/releases/2023/03/230317145038.htm A new substance has proven useful for treating staphylococcus infections in people with skin lymphoma. This is good news for the patients, but also for the global threat of antibiotics resistance. Fri, 17 Mar 2023 14:50:38 EDT //www.koonmotors.com/releases/2023/03/230317145038.htm //www.koonmotors.com/releases/2023/02/230213120656.htm The most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumour cells must do to survive. Researchers found that cancer cells use signals to attract certain types of immune cell and instruct them not to attack. Mon, 13 Feb 2023 12:06:56 EST //www.koonmotors.com/releases/2023/02/230213120656.htm //www.koonmotors.com/releases/2023/01/230124101558.htm The value of chemotherapy delivery at specific times of the day to optimize efficacy and minimize adverse effects in hematologic malignancy remains unknown. An interdisciplinary research team discovers its benefit by analyzing cohorts of diffuse large B cell lymphoma (DLBCL)* patients: Chemotherapy in the afternoon significantly improves treatment outcomes of female patients while there is no difference depending on treatment time in male patients. Tue, 24 Jan 2023 10:15:58 EST //www.koonmotors.com/releases/2023/01/230124101558.htm //www.koonmotors.com/releases/2023/01/230109112811.htm A research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. Mon, 09 Jan 2023 11:28:11 EST //www.koonmotors.com/releases/2023/01/230109112811.htm //www.koonmotors.com/releases/2022/12/221222123117.htm Researchers have demonstrated that people suffering from blood cancer have a good immune response to COVID-19 vaccinations. Vaccination protects patients with B-cell lymphoma and multiple myeloma against severe illness from COVID-19. Some patients even form highly potent antibodies. Thu, 22 Dec 2022 12:31:17 EST //www.koonmotors.com/releases/2022/12/221222123117.htm //www.koonmotors.com/releases/2022/11/221122111359.htm A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests. Tue, 22 Nov 2022 11:13:59 EST //www.koonmotors.com/releases/2022/11/221122111359.htm //www.koonmotors.com/releases/2022/10/221027124103.htm A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in mice. Thu, 27 Oct 2022 12:41:03 EDT //www.koonmotors.com/releases/2022/10/221027124103.htm //www.koonmotors.com/releases/2022/09/220908131853.htm Scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer predisposition. Thu, 08 Sep 2022 13:18:53 EDT //www.koonmotors.com/releases/2022/09/220908131853.htm //www.koonmotors.com/releases/2022/08/220824120842.htm An engineer has found a way to determine which patients are likely to respond to #CAR T-cell therapy, saving precious time in treating #lymphoma, which is most responsive to this form of #immunotherapy. Wed, 24 Aug 2022 12:08:42 EDT //www.koonmotors.com/releases/2022/08/220824120842.htm //www.koonmotors.com/releases/2022/07/220714144959.htm A study has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Thu, 14 Jul 2022 14:49:59 EDT //www.koonmotors.com/releases/2022/07/220714144959.htm //www.koonmotors.com/releases/2022/06/220628170158.htm There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to a recent analysis. Tue, 28 Jun 2022 17:01:58 EDT //www.koonmotors.com/releases/2022/06/220628170158.htm //www.koonmotors.com/releases/2022/06/220614164434.htm A new study shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells. Tue, 14 Jun 2022 16:44:34 EDT //www.koonmotors.com/releases/2022/06/220614164434.htm //www.koonmotors.com/releases/2022/06/220609131946.htm Researchers have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy. Thu, 09 Jun 2022 13:19:46 EDT //www.koonmotors.com/releases/2022/06/220609131946.htm //www.koonmotors.com/releases/2022/06/220603100050.htm Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported. Fri, 03 Jun 2022 10:00:50 EDT //www.koonmotors.com/releases/2022/06/220603100050.htm //www.koonmotors.com/releases/2022/05/220525131158.htm DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer, according to a new study. Wed, 25 May 2022 13:11:58 EDT //www.koonmotors.com/releases/2022/05/220525131158.htm //www.koonmotors.com/releases/2022/05/220513113234.htm In early research, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Fri, 13 May 2022 11:32:34 EDT //www.koonmotors.com/releases/2022/05/220513113234.htm //www.koonmotors.com/releases/2022/05/220512164045.htm A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). Thu, 12 May 2022 16:40:45 EDT //www.koonmotors.com/releases/2022/05/220512164045.htm //www.koonmotors.com/releases/2022/04/220428085830.htm Researchers identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of lymphomas. Thu, 28 Apr 2022 08:58:30 EDT //www.koonmotors.com/releases/2022/04/220428085830.htm //www.koonmotors.com/releases/2022/03/220310143730.htm A recent study followed 515 patients with varying cancers. The goal was to evaluate if patients had an immune response to the Moderna mRNA-1273 vaccine and if that response differed by diagnosis and treatment. Thu, 10 Mar 2022 14:37:30 EST //www.koonmotors.com/releases/2022/03/220310143730.htm //www.koonmotors.com/releases/2022/02/220228114343.htm Researchers have shared a comprehensive multiomics study from a rare cohort of 56 patients with transformed CTCL and identified several genomic alterations and oncogenic programs that may be potential novel therapeutic targets. Mon, 28 Feb 2022 11:43:43 EST //www.koonmotors.com/releases/2022/02/220228114343.htm //www.koonmotors.com/releases/2022/01/220112105640.htm There are myriad reasons why cancers develop. By studying genes which are altered in people with lymphoma, a multidisciplinary team of researchers has identified a key mechanism involved in disease development. This signaling pathway, which the researchers describe in detail, controls the repair of DNA damage. Wed, 12 Jan 2022 10:56:40 EST //www.koonmotors.com/releases/2022/01/220112105640.htm //www.koonmotors.com/releases/2022/01/220103145607.htm Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a new study. Mon, 03 Jan 2022 14:56:07 EST //www.koonmotors.com/releases/2022/01/220103145607.htm //www.koonmotors.com/releases/2021/12/211214084535.htm Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests. 星期二,2021年12月14日08:45:35 EST //www.koonmotors.com/releases/2021/12/211214084535.htm //www.koonmotors.com/releases/2021/11/211104115344.htm New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell lymphoma (DLBCL) live. Thu, 04 Nov 2021 11:53:44 EDT //www.koonmotors.com/releases/2021/11/211104115344.htm //www.koonmotors.com/releases/2021/10/211013152106.htm For nearly a decade, scientists have known that HIV integrates itself into genes in cells that have the potential to cause cancer. And when this happens in animals with other retroviruses, those animals often develop cancer. But, perplexingly and fortunately, that isn't regularly happening in people living with HIV. A new study reveals why doctors aren't seeing high rates of T cell lymphomas -- or cancers of the immune system -- in patients with HIV. Wed, 13 Oct 2021 15:21:06 EDT //www.koonmotors.com/releases/2021/10/211013152106.htm //www.koonmotors.com/releases/2021/09/210903095314.htm Researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Fri, 03 Sep 2021 09:53:14 EDT //www.koonmotors.com/releases/2021/09/210903095314.htm //www.koonmotors.com/releases/2021/08/210824135319.htm New research has revealed a new fundamental feature of aggressive B-cell lymphomas which could open the door to further research into early detection and treatment of the disease. Tue, 24 Aug 2021 13:53:19 EDT //www.koonmotors.com/releases/2021/08/210824135319.htm //www.koonmotors.com/releases/2021/07/210701112647.htm More than 9 of 10 patients with cancer showed good immune response to the COVID-19 mRNA vaccines after receiving both doses, but subsets of high-risk patients did not, according to a new study. Thu, 01 Jul 2021 11:26:47 EDT //www.koonmotors.com/releases/2021/07/210701112647.htm //www.koonmotors.com/releases/2021/04/210414131954.htm Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled. Wed, 14 Apr 2021 13:19:54 EDT //www.koonmotors.com/releases/2021/04/210414131954.htm //www.koonmotors.com/releases/2021/04/210411114051.htm 早期的研究结果从一个新的、开拓嵌合抗gen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse. Sun, 11 Apr 2021 11:40:51 EDT //www.koonmotors.com/releases/2021/04/210411114051.htm //www.koonmotors.com/releases/2021/01/210126134105.htm Scientists have developed a novel therapy to trick cancer cells into gobbling up what they think is their favorite food - cholesterol -- which actually triggers their destruction. What appears to them as a cholesterol-loaded particle is actually a synthetic nanoparticle that binds to the cancer cells and starves them to death. The study was in lymphoma cells but could be effective in ovarian and kidney cancer. Tue, 26 Jan 2021 13:41:05 EST //www.koonmotors.com/releases/2021/01/210126134105.htm //www.koonmotors.com/releases/2021/01/210121132143.htm Researchers have discovered a new enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, a critical factor in EBV's ability to transform human cells and cause cancer. Study provides new indications for inhibiting EBNA1 function, opening up fresh avenues for development of therapies to treat EBV-associated cancers. 星期四,2021年1月21日13:21:43 EST //www.koonmotors.com/releases/2021/01/210121132143.htm //www.koonmotors.com/releases/2020/12/201217112957.htm The researchers discovered that cancer immunotherapies that make use of immune system cells such as T cells and CAR-T cells kill not only tumor cells that express the drugs' target, but also adjacent tumor cells that lack the targets, because of the presence of fas. This process, known as bystander killing, can be made more effective by adding therapeutics that turn off the regulation of fas proteins, the researchers said. Thu, 17 Dec 2020 11:29:57 EST //www.koonmotors.com/releases/2020/12/201217112957.htm //www.koonmotors.com/releases/2020/12/201216183707.htm Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes. Wed, 16 Dec 2020 18:37:07 EST //www.koonmotors.com/releases/2020/12/201216183707.htm //www.koonmotors.com/releases/2020/12/201207161535.htm Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers. Mon, 07 Dec 2020 16:15:35 EST //www.koonmotors.com/releases/2020/12/201207161535.htm //www.koonmotors.com/releases/2020/12/201205143404.htm A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, researchers report. Sat, 05 Dec 2020 14:34:04 EST //www.koonmotors.com/releases/2020/12/201205143404.htm //www.koonmotors.com/releases/2020/10/201011220803.htm A research team hsd discovered that certain exosomes can effectively control Epstein-Barr virus-associated tumors and induce T-cell anti-tumor immunity. The novel findings provide insights into new therapeutic approach for Epstein-Barr virus (EBV)-associated tumors. Sun, 11 Oct 2020 22:08:03 EDT //www.koonmotors.com/releases/2020/10/201011220803.htm //www.koonmotors.com/releases/2020/09/200928125010.htm 免疫系统会记住后病原体an infection and can therefore react promptly after reinfection with the same pathogen. Now, scientists have deciphered new details of this process. Mon, 28 Sep 2020 12:50:10 EDT //www.koonmotors.com/releases/2020/09/200928125010.htm //www.koonmotors.com/releases/2020/08/200818103823.htm Researchers describe a novel acidic niche within lymph nodes that plays an integral role in regulating T cell activation. Tue, 18 Aug 2020 10:38:23 EDT //www.koonmotors.com/releases/2020/08/200818103823.htm //www.koonmotors.com/releases/2020/07/200709085320.htm 科学家开发出了一种新的癌症疫苗的智慧h the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers. Thu, 09 Jul 2020 08:53:20 EDT //www.koonmotors.com/releases/2020/07/200709085320.htm //www.koonmotors.com/releases/2020/05/200530113632.htm Although lymphoma is one of the most common types of blood cancer, it has a rare subtype for which no effective treatment regimens are known. For the first time, researchers have conducted clinical trials for a new treatment protocol and report it to be quite promising. Sat, 30 May 2020 11:36:32 EDT //www.koonmotors.com/releases/2020/05/200530113632.htm //www.koonmotors.com/releases/2020/05/200512190005.htm A research team has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is the first known agent to successfully target the virus and disturb its latency in tumor cells in this way. Tue, 12 May 2020 19:00:05 EDT //www.koonmotors.com/releases/2020/05/200512190005.htm //www.koonmotors.com/releases/2020/05/200505093131.htm In an international collaboration, researchers have mapped the lymph node lymphatic vessels in mice and humans down to the level of individual cells. The results may eventually help scientists to discover new methods for strengthening the immune system against viruses and cancer. Tue, 05 May 2020 09:31:31 EDT //www.koonmotors.com/releases/2020/05/200505093131.htm //www.koonmotors.com/releases/2020/04/200423130457.htm Scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers like Non-Hodgkin lymphoma. Thu, 23 Apr 2020 13:04:57 EDT //www.koonmotors.com/releases/2020/04/200423130457.htm //www.koonmotors.com/releases/2020/02/200220104050.htm Researchers have revealed a new vulnerability in lymphomas that are driven by one of the most common cancer-causing changes in cells. The team hopes that this could be a new target for treating a range of cancers. Thu, 20 Feb 2020 10:40:50 EST //www.koonmotors.com/releases/2020/02/200220104050.htm //www.koonmotors.com/releases/2020/02/200213135800.htm Breakthrough cellular genomics technology has allowed researchers to reveal genetic mutations causing rogue behavior in the cells that cause autoimmune disease. Thu, 13 Feb 2020 13:58:00 EST //www.koonmotors.com/releases/2020/02/200213135800.htm //www.koonmotors.com/releases/2020/02/200205171647.htm According to results from a Phase I/IIa trial, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. Wed, 05 Feb 2020 17:16:47 EST //www.koonmotors.com/releases/2020/02/200205171647.htm //www.koonmotors.com/releases/2020/01/200121124018.htm Researchers have discovered ways to boost CAR T-cell therapy. Tue, 21 Jan 2020 12:40:18 EST //www.koonmotors.com/releases/2020/01/200121124018.htm //www.koonmotors.com/releases/2020/01/200115191525.htm There has been a measurable decline in serious heart conditions among adult survivors of childhood cancer since the 1970s, finds a new study. Wed, 15 Jan 2020 19:15:25 EST //www.koonmotors.com/releases/2020/01/200115191525.htm //www.koonmotors.com/releases/2019/11/191111180122.htm Researchers compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. Mon, 11 Nov 2019 18:01:22 EST //www.koonmotors.com/releases/2019/11/191111180122.htm //www.koonmotors.com/releases/2019/10/191028104154.htm A new study has found that the drug first forces itself between the strands of the DNA molecule's double helix, prying them apart. It then compacts the structures by partially neutralizing their phosphate backbones. Mon, 28 Oct 2019 10:41:54 EDT //www.koonmotors.com/releases/2019/10/191028104154.htm //www.koonmotors.com/releases/2019/10/191008133009.htm A new study shows the stage at which lymphoma is originally diagnosed impacts the types of second cancers that may form after treatment. Tue, 08 Oct 2019 13:30:09 EDT //www.koonmotors.com/releases/2019/10/191008133009.htm //www.koonmotors.com/releases/2019/10/191002181131.htm Investigators analyzed 40 years of cancer burden data and examined patterns of incidence and mortality for various cancers, finding examples for which incidence and mortality moved in concert and examples where discordance in incidence and mortality indicate that overdiagnosis may be at play. Wed, 02 Oct 2019 18:11:31 EDT //www.koonmotors.com/releases/2019/10/191002181131.htm //www.koonmotors.com/releases/2019/09/190926141721.htm A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumours, may give clues to how cancers evade the immune system, according to a new study. Thu, 26 Sep 2019 14:17:21 EDT //www.koonmotors.com/releases/2019/09/190926141721.htm //www.koonmotors.com/releases/2019/08/190820081853.htm Scientists have developed a new gene editing system that could be used for anticancer immunotherapy through the simultaneous suppression of proteins that interfere with the immune system expressed on the surface of lymphoma cells and activation of cytotoxic T lymphocyte. Tue, 20 Aug 2019 08:18:53 EDT //www.koonmotors.com/releases/2019/08/190820081853.htm //www.koonmotors.com/releases/2019/08/190808103815.htm New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. Thu, 08 Aug 2019 10:38:15 EDT //www.koonmotors.com/releases/2019/08/190808103815.htm //www.koonmotors.com/releases/2019/08/190805101121.htm Researchers have developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation, an approach that also dramatically increased the success of the drugs in melanoma and lung cancer. Mon, 05 Aug 2019 10:11:21 EDT //www.koonmotors.com/releases/2019/08/190805101121.htm //www.koonmotors.com/releases/2019/07/190725102937.htm New research shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma. Thu, 25 Jul 2019 10:29:37 EDT //www.koonmotors.com/releases/2019/07/190725102937.htm //www.koonmotors.com/releases/2019/07/190725092538.htm Investigators have created a new method that could make immune therapy more effective again brain tumors and expand its use against other types of solid tumors. Thu, 25 Jul 2019 09:25:38 EDT //www.koonmotors.com/releases/2019/07/190725092538.htm //www.koonmotors.com/releases/2019/07/190722182141.htm Researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). They've developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth. Mon, 22 Jul 2019 18:21:41 EDT //www.koonmotors.com/releases/2019/07/190722182141.htm